Synthetic cannabinoid URB447 reduced brain injury and white matter damage in newborn rats after oxygen deprivation

What the researchers found

URB447 strongly reduced brain injury when given before hypoxia-ischemia. When given 3 hours after injury (a clinically feasible window), it still reduced neurodegeneration, white matter damage, astrogliosis, and microglial activation. The CB1 antagonist SR141716A had a comparable protective effect, while the CB1 agonist WIN-55,212-2 reduced URB447's benefit.

Why it matters

Perinatal brain injury from oxygen deprivation affects roughly 1-3 per 1,000 live births and has limited treatment options. A 3-hour therapeutic window is clinically relevant for treating affected newborns.

The numbers in context

URB447 reduced neurodegeneration and white matter damage when given 3 hours post-injury. CB1 agonist WIN-55,212-2 diminished URB447's protective effect, pointing to CB2 activation and CB1 blockade as the mechanism.

How the study worked

Neonatal rat model of hypoxia-ischemia. URB447 (a CB1 antagonist/CB2 agonist) administered either before or 3 hours after injury. Effects compared with CB1 antagonist SR141716A and CB1 agonist WIN-55,212-2. Brain injury, white matter damage, and inflammatory markers assessed histologically.

What this study cannot tell us

Animal model; neonatal rat brain development does not perfectly match human timing; single compound studied; long-term functional outcomes not assessed.

How to read the evidence

Single animal study in neonatal rats; no long-term functional outcome data.

When this study was published

Published in 2020.

The bigger picture

The finding that CB1 blockade combined with CB2 activation provides neuroprotection adds nuance to the role of the endocannabinoid system in brain injury, where different receptor subtypes may play opposing roles.

Questions still open

• Would URB447 provide neuroprotection in human neonates? Could this approach complement existing hypothermia therapy for perinatal brain injury?

Common questions

Read the original research

The Synthetic Cannabinoid URB447 Reduces Brain Injury and the Associated White Matter Demyelination after Hypoxia-Ischemia in Neonatal Rats.

ACS chemical neuroscience, 11(9), 1291-1299

Citation

Carloni, Silvia; Crinelli, Rita; Palma, Linda; Álvarez, Francisco J; Piomelli, Daniele; Duranti, Andrea; Balduini, Walter; Alonso-Alconada, Daniel. (2020). The Synthetic Cannabinoid URB447 Reduces Brain Injury and the Associated White Matter Demyelination after Hypoxia-Ischemia in Neonatal Rats.. ACS chemical neuroscience, 11(9), 1291-1299. https://doi.org/10.1021/acschemneuro.0c00047

Explore the wider topic

• How THC Affects Your Amygdala: The Brain's Threat Detector and Cannabis
• The Anandamide Connection: Your Body's Natural Bliss Molecule
• How Long for Cannabinoid Receptors to Return to Normal
• Cannabis and the Developing Brain: What Every Teenager (and Parent) Should Know
• Why Can't I Enjoy Anything Without Weed? The Science Behind It
• Dopamine Recovery After Quitting Weed: What the Science Says
• The Endocannabinoid System Explained Simply: What It Does and Why It Matters
• Your Endocannabinoid System Explained: Why Withdrawal Happens
• Your Nervous System After Quitting Weed: Fight or Flight
• Using Weed Under 18: What It Does to Your Developing Brain
• What THC Does to Your Brain: Why Withdrawal Happens
• THC and Your Prefrontal Cortex: What Cannabis Does to Your Decision-Making Brain
• Weed, Cortisol, and Stress: What Cannabis Does to Your Stress Hormones
• Weed and Memory: What the Science Says About THC and Your Hippocampus
• Weed and Motivation: Is Amotivational Syndrome Real?
• Weed and Your Nervous System: What THC Actually Does to Your Brain and Body
• How Weed Rewires Your Reward System (And How to Reset It)